Tobramycin (tobramycin) - Dosing, PA Forms & Info (2026)
logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Tobramycin

    Get your patient on Tobramycin

    Medication interactionsSee all drug-to-drug interactions for this medication.
    card icon
    Prescribing informationPubMed™ news

    Tobramycin prescribing information

    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    Prescribing Information
    Indications & Usage

    INDICATIONS AND USAGE

    Tobramycin ophthalmic solution 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

    Dosage & Administration

    DOSAGE AND ADMINISTRATION

    In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

    Contraindications

    CONTRAINDICATIONS

    Tobramycin ophthalmic solution 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

    Adverse Reactions

    ADVERSE REACTIONS

    The most frequent adverse reactions to tobramycin ophthalmic solution 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution.

    Postmarketing Experience: Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.

    The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.

    To report SUSPECTED ADVERSE REACTIONS, contact Jvet Pharmaceuticals, LLC at 1-727-292-1166 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Description

    DESCRIPTION

    Tobramycin ophthalmic solution USP, 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.

    Each mL of tobramycin ophthalmic solution USP, 0.3% contains: Active: tobramycin 0.3 % (3 mg). Preservative: benzalkonium chloride 0.01 % (0.1 mg). Inactives: boric acid, sodium sulfate decahydrate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and water for injection. Tobramycin ophthalmic solution USP, 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260-320 mOsm/kg.

    Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.

    The chemical structure of tobramycin is:

    Referenced Image


    Molecular Weight = 467.52
    Molecular Formula: C 18 H 37 N 5 O 9

    Chemical name:
    O-3-Amino-3-deoxy-α-D-glucopyranosyl-(1→4)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-L-streptamine.

    Pharmacology

    CLINICAL PHARMACOLOGY

    In Vitro Data: In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

    Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae .

    Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

    How Supplied/Storage & Handling

    HOW SUPPLIED

    5 mL sterile solution supplied in opaque white low density polyethylene bottle which is closed with natural low density polyethylene nozzle and then with Tan colored high density polyethylene cap as follows:

    5 mL containing tobramycin 0.3% (3 mg/mL)……….. NDC 86211-110-01

    Storage: Store at 2°C to 25°C (36°F to 77°F).

    After opening, Tobramycin Ophthalmic Solution, USP 0.3% can be used until the expiration date on the bottle.

    Distributed by:
    Jvet Pharmaceuticals LLC

    6925112th Circle North, Suite 101

    Largo, FL 33773

    Revised: May 2025

    L110I-VTN R-2505

    747

    1313001232-00

    Data SourceWe receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
    Report Adverse Event
    Interactions Banner
    Check medication interactionsReview interactions as part of your prescribing workflow

    Tobramycin PubMed™ news

      Show the latest PubMed™ articles for Tobramycin